Since aberrant expression of DUX4 was identified as a major factor in the etiology of facioscapulohumeral dystrophy (FSHD), several therapeutic approaches were developed to inhibit its expression in this context and could be potentially useful to treat DUX4-rearranged ALL. This evidence concerns the gene DUX4 and acute lymphoblastic leukemia.